LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Închisă

3.31 -0.6

Rezumat

Modificarea prețului

24h

Curent

Minim

3.24

Maxim

3.33

Indicatori cheie

By Trading Economics

Venit

44M

-26M

Vânzări

-5.8M

42M

Marjă de profit

-61.388

Angajați

550

EBITDA

44M

-22M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+21.43% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

206M

1.3B

Deschiderea anterioară

3.91

Închiderea anterioară

3.31

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 dec. 2025, 15:21 UTC

Câștiguri

Correction to Home Depot Outlook Headline on Dec. 9

23 dec. 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dec. 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 dec. 2025, 21:21 UTC

Achiziții, Fuziuni, Preluări

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dec. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

St Barbara to Hold Deposit in Escrow

23 dec. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dec. 2025, 21:19 UTC

Achiziții, Fuziuni, Preluări

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dec. 2025, 21:13 UTC

Achiziții, Fuziuni, Preluări

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dec. 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dec. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dec. 2025, 19:13 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dec. 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23 dec. 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dec. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

23 dec. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 dec. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23 dec. 2025, 17:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dec. 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dec. 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dec. 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23 dec. 2025, 16:03 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank: Closing Expected Around Mid-January

23 dec. 2025, 16:03 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dec. 2025, 16:02 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dec. 2025, 16:01 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dec. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dec. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Telefonica Doesn't Set Out Financial Details of Divestment

23 dec. 2025, 15:41 UTC

Achiziții, Fuziuni, Preluări

Telefonica: Deal Will Allow Focus on Core Markets

23 dec. 2025, 15:40 UTC

Achiziții, Fuziuni, Preluări

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dec. 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Comparație

Modificare preț

Maravai LifeSciences Holdings Inc (Class A) Așteptări

Obiectiv de preț

By TipRanks

21.43% sus

Prognoză pe 12 luni

Medie 4.25 USD  21.43%

Maxim 4.5 USD

Minim 4 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMaravai LifeSciences Holdings Inc (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

3

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.02 / 2.115Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat